Worst performer for the 2nd week in a row was SBTX:SkinBioTherapeutics, which dropped 59% after it was revealed that the CEO was being investigated for mis-reporting revenues. This was on top of last week's 39% drop, which has sent my holding down by around 78% when they were fairly close to break-even just 2 weeks ago. All I can hope is that they get to the bottom of the issue and that it doesn't affect the fundamental promise of the company.
My next worst performer was a bit of spectacularly bad timing. Although I haven't anywhere near finished re-doing my AIM magic formula ranking, DXRX:Diaceutics scored very well and was right near the top. They appeared to have good momentum and had forecast being profitable in 2026. They had recently shot up after a big drop, and I figured momentum was with them and now was a good time to buy, so I did. I was wrong, and they promptly fell 12% for no reason I could fathom. They do seem to have a history of volatile price movements, so I just hope they reverse this drop soon.
FDM:FDM Group continue to slide. They fell another 10% this week to go 56% down, but I think it's way over-done and will hold for when people start hiring staff again.
AMRQ:Amaroq announced they were moving from AIM to the LSE main market and de-listing from the Canadian market. I thought that was good news, but it resulted in loads of sales and the price dropped 8%. I took advantage of the drop and bought some in my SIPP, as I reckon this qualifies now it's moving off AIM and will hopefully soon be paying a dividend.
IHP:Integrafin was profitable and doing well a few weeks ago, but has been slipping and dropped 5% this week to go 8% down. I won't be buying any more though, as they have slipped out of the top 30 ranking.
IPX:Impax Asset Management dropped 5% so any hopes I had of these staging a recovery have been put on hold.
JLP:Jubilee Metals gave what I thought were pretty good results in their operational update, but still fell 5%. I don't know if it's because no financial figures were mentioned, but there was good growth in production so I really thought it would trigger some recovery, but no.
CAML:Central Asia Metals had another steady week, climbing 5% to go 39% up in my SIPP with £949 potential profit.
GAW:Games Workshop also rose 5% and the top-up from last week is now contributing to potential profits of £893 as my holding is up by 40%.
PRU:Prudential crashed unexpectedly last week, but recovered 6% this week to go 15% up with £166 potential profit.
ATYM:Atalya Mining went up 8% and although they are still below what I paid in the recent placing, they are in the black by 5% and back into potential profit of £156.
PBX:Probiotix Health recovered 8% after distancing themselves from the antics at SBTX:SkinBioTherapeutics. My holding is still down by 66% though and losing around £13,500.
AMP:Ampeak Energy went up 11% but are still 62% down and losing £623.
PAF:Pan African Resources is really my star share, and went up another 16% after results, so my holding is up by 449% and making £7,950 potential profit. Imagine if I hadn't sold so many on the way up!
I really thought AFC:AFC Energy were going to win Share of the Week as they continue to charge upwards after the announcement of the JV to modify diesel engines to run on ammonia and hydrogen. They went up another 21% this week and my holding is only 1% down with a loss of just £20. Will it go into profit next week or will the profit-takers strike?
The unexpected Share of the Week is W7L:Warpaint London, which zoomed up 29% on the back of last week's trading update. My holding went into profit and is 16% up making £186 potential profit. A very rare bit of good timing.
Here's the ISA and shares portfolio after week 30 of year 11.
| Weekly Change | |||
| Cash | £111.32 | +£23.59 | |
| Portfolio cost | £117,391.60 | +£515.91 | |
| Portfolio sell value (bid price-commission) | £38,558.23 | (-67.2%) | -£2,931.78 |
| Potential profits | £379.44 | -£659.36 | |
| Yr 11 Dividends | £69.36 | +£0 | |
| Yr 11 Interest | £0.85 | +£0.05 | |
| Yr 11 Profit from sales | £1,066.50 | +£539.44 | |
| Yr 11 proj avg monthly profit | £156.22 | (2.1%) | +£74.59 |
| Total Dividends | £12,557.43 | +£0 | |
| Total Interest | £9.42 | +£0.05 | |
| Total Profit from sales | £18,626.77 | +£539.44 | |
| Average monthly cash profit | £240.07 | (3.3%) | +£3.78 |
| (Sold stocks profit + Dividends - Fees / Months) |
When I said I was going to have a quiet week, I lied. Partly due to discovering DXRX:Diaceutics and partly due to JP Morgan appearing to borrow a load of CWR:Ceres Power shares presumably to support shorting activity, I decided to sell CWR. I sold my 538 shares at 309.8408p making £539.44 (48.5%) profit. I bought 643 shares in DXRX at 167.8p costing £1,083.95 and I planned to keep the rest to buy back into CWR when they next drop significantly. However, when AMRQ:Amaroq announced they were moving to the main market, I bought 490 shares at 112.1333p costing £554.45. I don't fancy playing games with shorters for CWR, as it's going to be a stressful ride.
Even without me taking profits, the portfolio value would still have dropped over £2,000, mainly due to all my biggest holdings dropping and the massive collapse in the SBTX:SkinBioTherapeutics share price, but it's the first time I've sold anything for a profit in a while.
Annoying that the upwards surge was so short lived.
Virtually back down to the trend line.
A teensy tick up but not enough to get back to the position I was in 12 months ago.
A great week for the SIPP, climbing in value by over £2,000 even though I took £244 profits. Once again I fibbed about having a quiet week, but that was directly caused by the announcement that AMRQ :Amaroq is moving off AIM to the main market. I had to get some in my SIPP.
Annoying that the upwards surge was so short lived.
Virtually back down to the trend line.
A teensy tick up but not enough to get back to the position I was in 12 months ago.
The SIPP looks like this after week 534 overall and week 14 of year 11.
| Weekly Change | ||||
| Cash | £1,412.71 | -£3.59 | ||
| Portfolio cost | £151,445.09 | +£244.48 | ||
| Portfolio sell value (bid price - commission) | £93,700.24 | (-38.1%) | +£2,057.00 | |
| Potential profits | £16,499.17 | +£2,424.82 | ||
| Yr 11 Dividends | £500.16 | +£0 | ||
| Yr 11 Interest | £6.26 | +£0.19 | ||
| Yr 11 Profit from sales | £5,762.12 | +£244.80 | ||
| Yr 11 proj avg monthly profit | £1,921.31 | (24.1%) | -£67.50 | |
| Total Dividends | £18,720.36 | +£0 | ||
| Total Interest | £26.96 | +£0.19 | ||
| Total Profit from sales | £30,428.63 | +£244.80 | ||
| Average monthly cash profit | £385.40 | (4.8%) | +£1.23 |
A great week for the SIPP, climbing in value by over £2,000 even though I took £244 profits. Once again I fibbed about having a quiet week, but that was directly caused by the announcement that AMRQ :Amaroq is moving off AIM to the main market. I had to get some in my SIPP.
First I sold HSX:Hiscox because although still in the top 50 in my magic formula, it's only just in the top 50. I sold my 75 shares at 1445.5756p and made a stunning £5.87 (0.5%) profit. I didn't mind because I was just liberating finds for AMRQ. I also sold another 15 shares in RIO:Rio Tinto at 7108.5132p and made £238.94 (28.8%) profit. That still leaves me with 55 shares and a value of £3,904, so I won't want to sell any more.
I used the proceeds to buy 2,027 shares in AMRQ at 104.75p costing £2,132.23. I'm happy to say they recovered to 107p by the end of the week, so my new holding is £27 in profit.
This account wasn't impacted as badly by the drops in JLP:Jubilee Metals, OPTI:Optibiotix and SBTX:SkinBioTherapeutics, in fact potential profits went up a massive £2,424, so it was a really good week.
Although a good week, it wasn't quite good enough to take us back above the injection line, but we're almost touching it.
A welcome reversal of last week's drop, and the trend line is pretty close to going flat.
Just enough profit to keep the long-term performance flat and still comfortably above the trend line.
JLP:Jubilee Metals staged a late surge after the bell on Friday, but too late to impact the bid price I use for my valuation. I don't know if it will immediately drop back again on Monday, or if we have finally got to the point where it starts going up. The value of the JLP operation massively exceeds the share price, and I really think the time has come for it to start climbing. If it does start breaking out, then my SIPP will liberate £18,700 for investing in magic formula shares and make £6,860 profit. That same rise to 11.5p would mean my ISA holding would be worth £45,500 and be making £22,000 potential profit. Even with all my microbiome shares in the depths of despair, that would massively improve my outlook. Here's to JLP hitting 11.5p.
Although a good week, it wasn't quite good enough to take us back above the injection line, but we're almost touching it.
A welcome reversal of last week's drop, and the trend line is pretty close to going flat.
Just enough profit to keep the long-term performance flat and still comfortably above the trend line.
JLP:Jubilee Metals staged a late surge after the bell on Friday, but too late to impact the bid price I use for my valuation. I don't know if it will immediately drop back again on Monday, or if we have finally got to the point where it starts going up. The value of the JLP operation massively exceeds the share price, and I really think the time has come for it to start climbing. If it does start breaking out, then my SIPP will liberate £18,700 for investing in magic formula shares and make £6,860 profit. That same rise to 11.5p would mean my ISA holding would be worth £45,500 and be making £22,000 potential profit. Even with all my microbiome shares in the depths of despair, that would massively improve my outlook. Here's to JLP hitting 11.5p.
I guess I should also mention that if it ever gets to the same value as PAF:Pan African Resources at 167p, then my ISA holding would be worth £661k and I could afford to retire!
No comments:
Post a Comment